Vertex Pharma concludes Phase 2 epilepsy trial
The study recruited and dosed people who did not benefit from the use of at least two currently available medicines for partial epilepsy. In the study, the patients
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly and Company’s (Lilly) olomorasib as a potential treatment for adults with advanced pancreatic cancer who have already received at least one prior systemic therapy.